Therapeutic Drug Monitoring of Nirmatrelvir/Ritonavir (Paxlovid) in Patients Treated for COVID-19: Results From a Prospective Multicenter Observational Study
The plasma trough concentrations of nirmatrelvir and ritonavir in patients treated for symptomatic COVID-19 were higher than the reference values of 2210 ng/mL for nirmatrelvir and 360 ng/mL for ritonavir stated in the product characteristics. Advanced age and renally eliminated comedication were identified as possible influencing factors that warrant further investigation.
Authors
- Torben Brod (ORCID: https://orcid.org/0000-0002-5088-9931)
- Dirk O. Stichtenoth (ORCID: https://orcid.org/0000-0002-6526-0917)
- Hans Worthmann (ORCID: https://orcid.org/0000-0002-3680-6407)
- Jens Martens‐Lobenhoffer (ORCID: https://orcid.org/0000-0002-3829-7992)
- Corinna R. Böger
Institutions
- Medizinische Hochschule Hannover (DE)
- Otto-von-Guericke-Universität Magdeburg (DE)
Publication Details
- Journal
- Therapeutic Drug Monitoring
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1097/ftd.0000000000001290
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00